FY2025 · ended Dec 31, 2025 · Revenue $1.20M, -49.9% YoY · Filed Mar 17, 2026
Longeveron Inc. (LGVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 million and a net loss of $22.7 million. Free cash flow was -$18.9 million. As of Jun 30, 2026 it held $18.1 million in cash and investments and $581,000 in total debt.
Revenue (TTM)
$1.19M
-42.7% vs year-ago TTM
Net income (TTM)
$-23.47M
-26.6% vs year-ago TTM
Operating cash flow (TTM)
$-20.37M
-40.4% vs year-ago TTM
Free cash flow (TTM)
$-20.53M
-35.6% vs year-ago TTM
EPS (TTM)
$-0.00
+48.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$17.52M
as of Jun 30, 2026
Operating margin
-1992.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LGVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1721484
- Former names
- LONGEVERON LLC (until Feb 10, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $2.4M | $709,000 | $1.2M | $1.3M |
| Operating income | -$23.3M | -$16.5M | -$21.0M | -$18.0M | -$17.5M |
| Net income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | -$17.0M |
| Diluted EPS | -$1.29 | -$2.62 | -$10.22 | -$0.90 | — |
| Operating cash flow | -$18.6M | -$13.9M | -$19.0M | -$14.0M | -$9.6M |
| Free cash flow | -$18.9M | -$14.5M | -$19.3M | -$14.5M | -$10.0M |
| Total assets | $10.3M | $25.6M | $12.1M | $27.4M | $42.8M |
| Total liabilities | $4.6M | $3.7M | $5.3M | $6.9M | $5.3M |
| Stockholders' equity | $5.7M | $21.9M | $6.7M | $20.5M | $37.5M |
| Cash and investments | $8.2M | $19.2M | $5.4M | $10.5M | $35.1M |
| Total debt | $824,000 | $1.4M | $2.0M | $2.0M | $5.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 14, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 24, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 19, 2026 | Aug 17, 2026 |
All 530 Longeveron Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.